Form 8-K VERTEX PHARMACEUTICALS For: May 06

Go back to Form 8-K VERTEX PHARMACEUTICALS For: May 06

Vertex (VRTX) PT Raised to $424 at RBC Capital

May 7, 2024 6:21 AM EDT

RBC Capital analyst Brian Abrahams raised the price target on Vertex (NASDAQ: VRTX) to $424.00 (from $417.00) while maintaining a Sector Perform rating.

The analyst comments "A solid 1Q optically, with WW CF sales exceeding expectations, though this was driven mainly by ex-U.S.... More

Vertex (VRTX) PT Lowered to $-- at Stifel

May 7, 2024 6:13 AM EDT

Stifel analyst Paul Matteis lowered the price target on Vertex (NASDAQ: VRTX) to $-- (from $430.00) while maintaining a Hold rating.

The analyst comments "We remain Hold rated on VRTX. The CF franchise posted a beat (helped by inventory) while VRTX reiterated their... More